全福生物科技股份有限公司
全福生物科技股份有限公司在台灣從事藥物研發，致力於對抗與治療疾病。主導產品為 BRM421（胜肽藥物，已完成治療乾眼症之臨床三期試驗）。研發管線亦包含治療神經經營性角膜炎的 BRM424、青光眼的 BRM411、濕性老年性黃斑部病變的 BRM412 眼藥水，以及治療退化性關節炎的 BRM521。公司成立於 2013 年，總部位於台灣台北市。
今日上漲 2.98%，股價站回短期均線。該股 RSI(6) 為 71.0，處於偏高區間，短線追高風險提升。股價站上5日、20日、60日、120日均線。短中期均線呈多頭排列，趨勢偏多。KD 指標中性（K=71.5）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | +249 | 0 | 0 | +249 |
| 09-23 | -80 | 0 | +7 | -73 |
| 09-22 | -381 | 0 | +2 | -379 |
| 09-21 | -555 | 0 | +8 | -547 |
| 09-18 | +130 | 0 | +3 | +133 |
| 09-17 | +591 | 0 | +1 | +592 |
| 09-16 | +182 | 0 | -1 | +181 |
| 09-15 | -82 | 0 | -3 | -85 |
| 09-14 | -194 | 0 | -3 | -197 |
| 09-11 | +250 | 0 | -14 | +236 |
| 09-10 | -143 | 0 | +4 | -139 |
| 09-09 | +111 | 0 | 0 | +111 |
| 09-08 | +148 | 0 | +17 | +165 |
| 09-07 | +59 | 0 | 0 | +59 |
| 09-04 | +160 | 0 | -1 | +159 |
| 09-03 | -181 | 0 | +2 | -179 |
| 09-02 | -25 | 0 | -2 | -27 |
| 09-01 | +43 | 0 | +1 | +44 |
| 08-31 | -84 | 0 | -2 | -86 |
| 08-28 | -98 | 0 | -6 | -104 |
| 08-27 | -704 | 0 | +11 | -693 |
| 08-26 | +27 | 0 | +1 | +28 |
| 08-25 | +4 | 0 | 0 | +4 |
| 08-24 | +51 | 0 | 0 | +51 |
| 08-21 | +14 | 0 | 0 | +14 |
| 08-20 | +30 | 0 | 0 | +30 |
| 08-19 | +33 | 0 | 0 | +33 |
| 08-18 | +15 | 0 | 0 | +15 |
| 08-17 | +4 | 0 | 0 | +4 |
| 08-14 | -162 | 0 | -1 | -163 |
| 08-13 | +19 | 0 | 0 | +19 |
| 08-12 | -99 | 0 | 0 | -99 |
| 08-11 | -107 | 0 | -1 | -108 |
| 08-10 | -87 | 0 | +1 | -86 |
| 08-07 | +49 | 0 | -19 | +30 |
| 08-06 | -6 | 0 | 0 | -6 |
| 08-05 | +58 | 0 | 0 | +58 |
| 08-04 | -87 | 0 | 0 | -87 |
| 08-03 | +7 | 0 | -3 | +4 |
| 07-31 | +9 | 0 | +1 | +10 |
| 07-30 | -31 | 0 | -3 | -34 |
| 07-29 | +35 | 0 | 0 | +35 |
| 07-28 | +31 | 0 | 0 | +31 |
| 07-27 | +49 | 0 | 0 | +49 |
| 07-24 | -11 | 0 | -1 | -12 |
| 07-23 | -41 | 0 | +2 | -39 |
| 07-22 | +19 | 0 | -4 | +15 |
| 07-21 | -40 | 0 | -1 | -41 |
| 07-20 | +107 | 0 | +4 | +111 |
| 07-17 | +14 | 0 | -1 | +13 |
| 07-16 | +18 | 0 | +1 | +19 |
| 07-15 | +40 | 0 | -15 | +25 |
| 07-14 | +98 | 0 | 0 | +98 |
| 07-13 | +10 | 0 | +29 | +39 |
| 07-09 | +44 | 0 | -3 | +41 |
| 07-08 | -74 | 0 | 0 | -74 |
| 07-07 | +67 | 0 | -2 | +65 |
| 07-06 | +9 | 0 | 0 | +9 |
| 07-03 | +17 | 0 | +2 | +19 |
| 07-02 | -2 | 0 | 0 | -2 |
| 07-01 | -15 | 0 | +1 | -14 |
| 06-30 | +27 | 0 | 0 | +27 |
| 06-29 | +8 | 0 | 0 | +8 |
| 06-26 | -109 | 0 | -2 | -111 |
| 06-25 | -24 | 0 | 0 | -24 |
| 06-24 | +97 | 0 | +1 | +98 |
| 06-22 | -45 | 0 | -4 | -49 |
| 06-18 | -51 | 0 | -1 | -52 |
| 06-17 | +62 | 0 | +4 | +66 |
| 06-16 | +43 | 0 | +1 | +44 |
| 06-15 | +41 | 0 | +2 | +43 |
| 06-12 | +10 | 0 | +6 | +16 |
| 06-10 | -325 | 0 | +10 | -315 |
| 06-09 | -601 | 0 | -24 | -625 |
| 06-08 | -172 | 0 | +12 | -160 |
| 06-04 | +5 | 0 | +6 | +11 |
| 06-03 | -601 | 0 | -1 | -603 |
| 06-02 | +63 | 0 | +2 | +65 |
| 06-01 | +43 | 0 | +3 | +46 |
| 05-29 | +108 | 0 | -3 | +105 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/08 | 110 萬 | +31.5% | +157.1% |
| 2026/07 | 84 萬 | -64.7% | +108.7% |
| 2026/06 | 238 萬 | +189.3% | +491.5% |
| 2026/05 | 82 萬 | +7.3% | -27.9% |
| 2026/04 | 77 萬 | -36.4% | +2152.9% |
| 2026/03 | 120 萬 | +90.5% | +3548.5% |
| 2026/02 | 63 萬 | -36.0% | +1758.8% |
| 2026/01 | 99 萬 | -7.2% | +2890.9% |
| 2025/12 | 106 萬 | +56.5% | +3121.2% |
| 2025/11 | 68 萬 | -19.4% | +237.8% |
| 2025/10 | 84 萬 | +111.8% | +2454.6% |
| 2025/09 | 40 萬 | - | - |